Skip to content 
A new Republican push to cut off federal funding for certain NIH-backed animal studies has opened another front in the political war over gender medicine, research oversight, and taxpayer spending.
The immediate focus is a University of California, San Diego project tied to androgen exposure and reproductive biology, but the broader fight reaches far beyond a single grant.
Republicans are now asking appropriators to ban federal support for animal experiments involving interventions intended to alter sex-linked characteristics.
The latest push was reported by Fox News, which said Rep. Paul Gosar and more than a dozen GOP lawmakers want language in the fiscal 2027 appropriations process that would prohibit federal money from being used for what they describe as “transgender animal testing.”
According to Fox, the proposal would apply to studies involving drugs, surgery, or other interventions intended to change biological traits associated with sex.
The UC San Diego Grant Became the Main Flashpoint
At the center of the dispute is an NIH-funded UC San Diego project titled Androgen effects on the reproductive neuroendocrine axis.
NIH’s RePORTER database shows the project is funded through NICHD in 2026 and lists an award amount of $584,117.
The project description says its central hypothesis is that male levels of exogenous androgens can inhibit the female reproductive neuroendocrine axis through androgen receptor pathways.
A related UC San Diego clinical-trial page gives the research more concrete language. It says the study investigates whether male-level exogenous androgens inhibit the reproductive neuroendocrine axis in otherwise healthy females.
That framing matters because it shows the study is presented by the university and NIH as hormone and reproductive science with clinical relevance, not in the blunt political terms often used by critics.
Congress Already Turned the Issue Into a Public Hearing
The political groundwork for the current fight was laid months earlier. On February 6, 2025, the House Oversight Committee’s Subcommittee on Cybersecurity, Information Technology, and Government Innovation held a hearing titled “Transgender Lab Rats and Poisoned Puppies: Oversight of Taxpayer Funded Animal Cruelty.”
The committee website and the official congressional record confirm both the hearing title and the participation of White Coat Waste Project’s Justin Goodman, a leading critic of federally funded animal research.
That hearing made clear the issue was not only about animal welfare. It was also about political framing. Supporters of the crackdown argue taxpayers should not finance controversial studies tied to gender-related medicine, particularly when animals are involved.
Researchers and research advocates, by contrast, tend to describe such work as part of broader efforts to study endocrine systems, fertility, reproductive suppression, and the biological effects of hormone exposure.
NIH Is Moving Toward Alternatives as the Political Pressure Rises
The timing also matters. In 2025, some NIH grants tied to gender identity and related fields became entangled in a larger legal and political battle over terminated research funding.
While the Fox article frames the current fight as a fresh act of congressional oversight, it also lands in a climate where lawmakers and advocacy groups are pressing NIH to justify not only what it funds, but how it explains the public value of that research.
At the same time, NIH is already signaling that the future of biomedical research may rely less on traditional animal models.
In March 2026, the agency announced more than $150 million in funding for human-based research methods designed to reduce reliance on animal testing.
NIH said the investment would support lab-based and computational approaches that better simulate human biology, including work under its Complement-ARIE program.
The Budget Fight Will Decide What Comes Next
That leaves Congress and NIH on intersecting tracks. One side is trying to cut off funding through appropriations and political pressure. The other is moving, at least in part, toward alternatives through scientific development and administrative policy.
Whether the Gosar-led effort gains traction will depend on the budget process ahead, but the dispute already shows how biomedical research can become a proxy war over culture, science, and federal power.
